Overview
The U.S. Food and Drug Administration expanded the indication for palbociclib to include maintenance treatment in certain patients with hormone receptor–positive, HER2-positive advanced or metastatic breast cancer.
The decision reflects results from the Phase III PATINA trial, which evaluated whether adding palbociclib to standard HER2-directed therapy and endocrine therapy could improve progression-free survival compared with HER2-directed therapy and endocrine therapy alone.
This summary highlights the trial design, primary efficacy outcome, and practical considerations for healthcare professionals reviewing publicly available regulatory information.
At a Glance
Key trial and regulatory context from the PATINA study and FDA review.
Research Background
PATINA was a randomized, open-label Phase III clinical trial conducted in patients with hormone receptor–positive, HER2-positive advanced or metastatic breast cancer.
Eligible participants had received prior treatment in the advanced or metastatic setting and continued on HER2-directed therapy and endocrine therapy as background treatment. The trial compared the addition of palbociclib versus no palbociclib on top of that backbone.
The primary endpoint was progression-free survival assessed by investigator review. Secondary endpoints included overall survival and patient-reported outcomes, among others.
Trial treatment arms
Key Findings
The primary analysis demonstrated a statistically significant improvement in progression-free survival with the addition of palbociclib.
Investigator-assessed progression-free survival favored the palbociclib arm versus control. Overall survival data were not mature at the time of the primary analysis and continued to be followed.
- Hazard Ratio: 0.76
- 95% Confidence Interval: 0.59–0.97
- Overall survival data remain immature.
Why It Matters
For clinicians managing HR+/HER2+ advanced breast cancer, maintenance strategies that delay progression without compromising tolerability remain an important clinical need.
Regulatory updates such as this provide a framework for understanding how cyclin-dependent kinase 4/6 inhibition may fit alongside established HER2-directed and endocrine therapies in selected patient populations, subject to approved labeling and local guidelines.
Safety Information
Safety findings should be interpreted alongside the full prescribing information and FDA materials.
In PATINA, adverse events observed with palbociclib were consistent with the known safety profile of CDK4/6 inhibitors, including hematologic effects and other class-related toxicities. Dose modifications and supportive care per protocol were permitted.
Healthcare professionals should review the complete FDA announcement, prescribing information, and institutional protocols before making treatment decisions.
View FDA announcement